eleva GmbH
General information
eleva GmbH
Hans-Bunte-Str. 19
79108 Freiburg, Baden-Württemberg
Germany
Contact person: Björn Cochlovius, Chief Executive Officer & Managing Director
Company main phone: +49 (761) 470990
Company main fax: +49 (761) 47099191
Website: https://www.elevabiologics.com
Hans-Bunte-Str. 19
79108 Freiburg, Baden-Württemberg
Germany
Contact person: Björn Cochlovius, Chief Executive Officer & Managing Director
Company main phone: +49 (761) 470990
Company main fax: +49 (761) 47099191
Website: https://www.elevabiologics.com
| Year founded: | 1999 |
| Source of foundation: | Independent foundation |
Corporate description / mission:
Eleva is a clinical-stage biopharmaceutical company focused on developing difficult-to-produce biologics within the healthcare sector. The company offers a drug development platform that specializes in complement disorders and enzyme replacement therapies, using a moss-based expression system for manufacturing. Eleva's primary offerings include therapies for orphan diseases, focusing on complement disorders and enzyme replacement therapies.
Eleva is a clinical-stage biopharmaceutical company focused on developing difficult-to-produce biologics within the healthcare sector. The company offers a drug development platform that specializes in complement disorders and enzyme replacement therapies, using a moss-based expression system for manufacturing. Eleva's primary offerings include therapies for orphan diseases, focusing on complement disorders and enzyme replacement therapies.
State of ownership: Private / independent
Headquarters: HQ: Yes
Headquarters: HQ: Yes
Remarks on ownership / listings
Eleva is a private equity-backed biopharmaceutical company.
Eleva is a private equity-backed biopharmaceutical company.
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Pre-clinical: | 2 | |
| Phase I: | 2 |
Description of products:
Recombinant Factor H (CPV-104) is expected to be a highly efficient complement regulator for the treatment of a broad range of complement conditions, including C3G, aHUS and PNH and AMD.
Glyco-optimized aGal (RPV-001) for the treatment of Fabry disease leads to improved organ targeting in a preclinical setup.
Recombinant Factor H (CPV-104) is expected to be a highly efficient complement regulator for the treatment of a broad range of complement conditions, including C3G, aHUS and PNH and AMD.
Glyco-optimized aGal (RPV-001) for the treatment of Fabry disease leads to improved organ targeting in a preclinical setup.
Technology used:
Moss-Based Technology
Moss-Based Technology
Collaborations & Clients
Partnering strategy / collaborations:
3PBiovian - strategic partnership
3PBiovian - strategic partnership
© 2026 Biotechgate by Venture Valuation